Ornopain(Lornoxicam)
Therapeutic Group: Nonsteroidal Anti-Inflammatory
Presentation
Ornopain 4: Each film coated tablet contains Lornoxicam INN 4 mg.
Ornopain 8: Each film coated tablet contains Lornoxicam INN 8 mg.
Description
Lornoxicam belongs to the oxicam group and is a non-steroidal anti-inflammatory drug (NSAID) with analgesic, anti-pyretic, anti-thrombotic, and anti-inflammatory activities. Upon oral administration, Lornoxicam binds to and inhibits the activity of the cyclooxygenase enzymes (COX) type 1 (COX-1) and type 2 (COX-2) by a ratio of 1:1. It readily penetrates into the synovial fluid. This leads to reduced prostaglandin and thromboxane production and decreased pain, fever, and inflammation.
Lornoxicam is well absorbed orally and has a half-life of around 3–4 hours. The onset of action can be observed
within 30–60 minutes of administration and eliminated via the liver and kidneys (42%).
Indications
It is indicated for the treatment of moderate to severe pain in osteoarthritis, rheumatoid arthritis, surgery, sciatica, dental pain and surgery, chronic low back pain, migraine, dysmenorrhea, and other inflammations.
Dosage & Administration
Pain: 8–16 mg of Lornoxicam daily, divided into 2 or 3 doses.
Osteoarthritis and Rheumatoid Arthritis: The initial recommended dose is 12 mg of Lornoxicam daily, divided into 2 or 3 doses. Maintenance doses should not exceed 16 mg of Lornoxicam daily. Should be taken in sufficient quantity
of liquid.
Children and adolescents: Lornoxicam is not recommended for use in children and adolescents below the age of 18.
Elderly: No special dosage modification is required for elderly patients above the age of 65.
Renal impairment: For patients with mild to moderate renal impairment, the maximum recommended daily dose is
12 mg, divided into 2 or 3 doses.
Hepatic impairment: For patients with moderate hepatic impairment, the maximum recommended daily dose is 12
mg divided into 2 or 3 doses.
Side Effects
Abdominal pain, diarrhea, indigestion, nausea, vomiting, headache, drowsiness, visual disturbance, ringing in the ear, sensitivity to light, high blood pressure, palpitations, and fluid retention may occur.
Precautions
It is not recommended to administer Lornoxicam to patients with history of hypersensitivity, impaired kidney function or liver function, heart failure, ulcerative colitis or Crohn’s disease, asthma, lupus erythematosus or blood
coagulation disorder.
Use in Pregnancy & Lactation
Lornoxicam is not recommended during pregnancy or breastfeeding and is contraindicated during the last three months of pregnancy.
Drug Interaction
Combination with vitamin K antagonists like warfarin increases the risk of bleeding. Combination with Cyclosporin can lead to reduced kidney function and acute kidney injury in rare cases. Lornoxicam can also increase the adverse effects of lithium, methotrexate, digoxin, and its derivatives. The effect of diuretics, ACE
inhibitors and angiotensin II receptor antagonists can be reduced in patients with heart failure.
Over Dose
Emergency measures, including gastric lavage, should be considered. Administering activated charcoal immediately after the intake of Lornoxicam can lead to diminished absorption of the preparation. Gastrointestinal disorders can be treated with a prostaglandin analogue or ranitidine.
Storage
Do not store above 30°C. Keep away from light and out of the reach of children.
Commercial Pack
Ornopain 4: Each box contains 3 blister strips of 10 tablets.
Ornopain 8: Each box contains 3 blister strips of 10 tablets.
